(MENAFN- Investor Brand Network) TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into a definitive agreement to acquire Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. Concurrent with the acquisition, TransCode secured a $25 million investment from CK Life Sciences Int'l (Holdings) Inc. to fund its lead microRNA candidate, TTX-MC138, through a Phase 2 clinical trial. Philippe Calais, PharmD, PhD, was appointed Chief Executive Officer, succeeding Interim CEO Tom Fitzgerald, who returns to his role as CFO.“This acquisition allows us to create a unique and broader oncology pipeline with Phase 3-ready seviprotimut-L and our TTX-MC138 program,” said Dr. Calais.“Together, these assets position TransCode to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.”

To view the full press release, visit

About TransCode Therapeutics

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company's newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN08102025000224011066ID1110168816